One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Integra Lifesciences Holdings Corp before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Integra Lifesciences Holdings Corp’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Integra Lifesciences Holdings Corp’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Integra Lifesciences Holdings Corp (IART)

Before we jump into Integra Lifesciences Holdings Corp’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company operates through two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS segment consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield and Bactiseal. Its product offering includes CereLink in the Unites States and Europe. The Company?s TT segment focuses on three areas, which include complex wound surgery, surgical reconstruction and peripheral nerve repair. TT's regenerative platform includes multiple brands, such as Integra Dermal Matrices, AmnioExcel, SurgiMend, MicroMatrix and NeuraGen. The Company's manufacturing and research facilities are located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland.

Want to learn more about Integra Lifesciences Holdings Corp’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Integra Lifesciences Holdings Corp. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Integra Lifesciences Holdings Corp’s Stock Price as of Market Close

As of April 26, 2023, 4:00 PM CST, Integra Lifesciences Holdings Corp’s stock price was $54.20.

Integra Lifesciences Holdings Corp is down 7.89% from its previous closing price of $58.84.

During the last market session, Integra Lifesciences Holdings Corp’s stock traded between $58.28 and $59.10. Currently, there are 83.12 million shares of Integra Lifesciences Holdings Corp stock available for purchase.

Integra Lifesciences Holdings Corp’s price-earnings (P/E) ratio is currently at 27.2, which is low compared to the Medical Equipment, Supplies & Distribution industry median of 39.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Integra Lifesciences Holdings Corp Stock Price History

Integra Lifesciences Holdings Corp’s (IART) price is currently down 5.59% so far this month.

During the month of April, Integra Lifesciences Holdings Corp’s stock price has reached a high of $59.33 and a low of $52.78.

Over the last year, Integra Lifesciences Holdings Corp has hit prices as high as $64.81 and as low as $40.67. Year to date, Integra Lifesciences Holdings Corp’s stock is down 19.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Integra Lifesciences Holdings Corp Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 25, 2023, there were 8 analysts who downgraded Integra Lifesciences Holdings Corp’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Integra Lifesciences Holdings Corp’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Integra Lifesciences Holdings Corp’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Integra Lifesciences Holdings Corp (IART) by visiting AAII Stock Evaluator.

Relative Price Strength of Integra Lifesciences Holdings Corp

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of April 25, 2023, Integra Lifesciences Holdings Corp has a weighted four-quarter relative price strength of 1.35%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Integra Lifesciences Holdings Corp is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Integra Lifesciences Holdings Corp Stock Price: Bottom Line

As of April 26, 2023, Integra Lifesciences Holdings Corp’s stock price is $54.20, which is down 7.89% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Integra Lifesciences Holdings Corp’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.